165 results about "Survival rate" patented technology

The invention specifically discloses an intelligent triage classification AR glasses system based on multi-modal data, and relates to the technical field of medical risk management. The system comprises an AR glasses hardware terminal module, a multi-modal data acquisition module, an intelligent analysis processing module, an AR man-machine interaction module, a data storage and transmission module and a peripheral linkage module. Wherein the AR glasses hardware terminal is in lightweight design, the multi-modal data acquisition module acquires and optimizes video, voice, physiology and other data of the wounded, the intelligent analysis processing module outputs red, yellow, green and black triage results through space-time alignment, feature fusion and AI analysis, the AR man-machine interaction module is used for optimizing interaction, and the data storage and transmission module guarantees data safety. And the peripheral linkage module realizes label printing and NFC writing. The system is short in single-time triage time, triage accuracy and environmental adaptability can be improved, information tracing is achieved, two hands of medical care are liberated, and rescue efficiency and the survival rate of wounded personnel are effectively improved.

The invention discloses a lung cancer patient dynamic survival prediction model based on multi-dimensional clinical data, and relates to the technical field of cancer survival prediction, and the key point of the technical scheme is that the dynamic survival prediction model comprises a core model module and a data support module, the core model module comprises a graph convolutional neural network model, a long-short-term memory network model and a generative large language model, and the data support module comprises three data processing systems, namely a time-dependent variable, a time independent variable and a data balancing strategy. According to the dynamic survival prediction model based on combination of traditional Chinese medicine and western medicine, abundant multivariate data in EHR can be fully utilized, individualized and precise diagnosis and treatment of the patient can be realized, artificial intelligence is assisted, and dynamic prediction of the survival rate of the lung cancer patient in one year, two years and three years can be effectively realized.

The invention discloses an application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma, relates to the technical field of disease prognosis and molecular biology, provides a marker for prognosis evaluation of diffuse large B-cell lymphoma, and relates to the application of NF-kappa B and IRF4 in prognosis evaluation of diffuse large B-cell lymphoma. The invention relates to application of a substance for detecting the marker in claim 1 in preparation of a product for prognosis evaluation of diffuse large B-cell lymphoma, and provides a medicine for treating diffuse large B-cell lymphoma. By detecting the marker, the malignancy degree of the DLBCL can be more accurately analyzed, a reliable prognosis evaluation basis is provided for clinicians, and accurate prognosis evaluation is carried out; through targeting NF-kappa B and MUM1 dual-blocking therapeutic drugs, the prognosis of patients is improved, the life quality and the survival rate of the patients are improved, and novel therapeutic drugs are developed; a new breakthrough is brought to diagnosis, treatment and prognosis evaluation of the DLBCL, and potential clinical application value is achieved.

The invention relates to the technical field of biological medicine, in particular to application of a creatine related gene detection reagent in preparation of breast cancer prognosis products. The creatine related gene is an IGFBP1 gene and / or a TBC1D4 gene. According to the method, the expression levels of IGFBP1 and TBC1D4 genes in breast cancer patient samples are detected, a risk score is calculated by using a random survival forest (RSF) model, and the one-year, two-year and three-year survival rates of breast cancer patients are accurately predicted according to the risk score result. Meanwhile, the invention proves that IGFBP1 and TBC1D4 genes can be used as potential targets for breast cancer treatment, the IGFBP1 and fulvestrant as well as the TBC1D4 and vinblastine have stable binding capacity, and a new basis is provided for selection of individualized treatment medicines for breast cancer.

The application provides a pig breeding and production integrated house group transfer planning and scheduling method and device, and relates to the technical field of intelligent breeding management. Through the fusion of health monitoring and reproductive performance double-dimensional data, the pigs are comprehensively rated and prioritized, so that the group transfer decision is no longer dependent on a single index or artificial experience, and high-value breeding pigs and pigs that need to be isolated can be accurately identified. In the process of combining pigs, the pig pathogen carrying state or health risk level is combined, and the same state priority merging principle is followed, so that the flow of different health state pigs is blocked, and biological safety control is strengthened. According to the loading scheme and the layout of the field, the target field is dynamically allocated and the transfer path is generated, the efficiency of the field is improved, and the stress of the pigs and the lag of the environmental control caused by the transfer confusion are reduced. Through scientific planning of the transfer process, the risk of disease outbreak and treatment cost are reduced, the smooth connection of each breeding link is ensured, and the survival rate of the pig group and the comprehensive breeding benefit are improved.

The invention provides an illness state tracking and early warning system based on a knowledge database, and the system comprises a data module which is responsible for collecting and integrating clinical knowledge and patient data information in the cardiovascular field; the survival rate prediction analysis module is used for extracting pathological features from the patient model, performing survival rate prediction analysis by using a deep learning algorithm and a neural network model, and displaying a prediction result to a physician in a visual report form; and the illness state auxiliary tracking, studying and judging module monitors the illness state change of the patient in real time, analyzes the illness state development trend and risk factors in combination with a knowledge graph and a patient model, and provides treatment scheme recommendation and early warning notification functions. Through the beneficial effects of integrating medical resources, improving data security, accurately predicting the survival rate of a patient, monitoring and early warning in real time, widely applying a knowledge graph, being friendly to user interaction, feedback circulation and continuous optimization and the like, powerful support is provided for prevention, diagnosis and treatment of cardiovascular diseases.

The invention provides a biomarker for predicting chemosensitivity of acute myelogenous leukemia and application of the biomarker, and belongs to the technical field of biological medicine. The leptin and fumaric acid provided by the invention can be used as biomarkers for predicting AML chemotherapy resistance. Wherein the leptin influences the chemotherapy sensitivity by regulating metabolic pathways such as mitochondrial OXPHOS and mitochondrial active oxygen mtROS; meanwhile, the invention also discloses a new mechanism that fumaric acid promotes BMSCs to transfer mitochondria to AML cells so as to enhance the OXPHOS level and induce Ara-C drug resistance. The levels of the two are obviously related to the chemotherapy reaction and prognosis stratification of the patient, so that early recognition of the patient with chemotherapy resistance or poor prognosis is facilitated. Leptin and fumaric acid can be detected in bone marrow plasma, the feasibility is high, and clinical transformation is facilitated. By detecting the level of leptin or fumaric acid in bone marrow of a patient, individualized treatment can be achieved, and the survival rate of the patient is increased.

The invention provides a connecting rod fatigue life evaluation method and device, electronic equipment and a storage medium, and the method comprises the steps: obtaining connecting rod fatigue life original data under multistage loads, constructing a structured data set, and training a deep neural network model according to the structured data set; predicting the life uncertainty of each load point in a preset target load range according to the trained network model, selecting the load point with the maximum life uncertainty to perform a fatigue test, and updating the network model according to a test result to obtain optimized S-N curve parameters and life distribution parameters; and based on the real-time load spectrum data, the optimized S-N curve parameters and the life distribution parameters, carrying out variable-amplitude load life calculation through a life distribution formula and a damage formula to obtain real-time fatigue life and damage contribution degree distribution under different preset survival rates. The accuracy of fatigue life evaluation of the connecting rod is improved, and accurate prediction and dynamic evaluation of the fatigue life under different survival rates are realized.

The invention relates to the field of biological medicines, and discloses application of serum EPSTI1 in preparation of a product for diagnosing liver cancer and evaluating whether a liver cancer patient is resistant to a revatinib or not. The invention provides a detection means which is convenient and rapid in sampling, small in risk and relatively low in cost, the content of EPSTI1 in serum is detected through an enzyme-linked immunosorbent assay, a liver cancer patient and a non-liver cancer patient can be effectively distinguished, and a lovatinib drug-resistant liver cancer patient and a non-drug-resistant liver cancer patient can be effectively distinguished. Prognosis analysis shows that the serum EPSTI1 can be used as a marker for evaluating the prognosis state of the liver cancer patient taking the lenvatinib, and has important significance in improving the survival rate of the liver cancer patient.

The invention discloses an ACS patient prognosis prediction method, which is characterized in that ACS patient prognosis is predicted through a trained and verified ACS patient prognosis prediction model, and prediction factors of the prediction model comprise patient age, heart rate, heart function grading, urea nitrogen and glycosylated hemoglobin. The predictive factors are screened by adopting multi-factor Cox regression analysis. The prediction model comprises a column chart model, and a column chart scale comprises a scale score range of 0-100, a patient age range of 25-95, a heart rate range of 40-140, a heart function grading range of I-IV, a urea nitrogen range of 0-35, a glycosylated hemoglobin range of 4-15, a total score range of 0-240 and a survival rate range of 0.99-0.01.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The present invention provides a body composition estimation program and information processing device that estimate body composition based on measurable values ​​without invasiveness. [Solution] Terminal 1 includes a lean body mass estimation means for estimating lean body mass based on the user's age, gender, height, and weight; a muscle mass estimation means for estimating muscle mass based on the user's age, gender, height, and weight; a sarcopenia determination means for determining the likelihood of sarcopenia based on at least one of lean body mass and muscle mass; a survival rate evaluation means 104 for evaluating the survival rate based on at least one of lean body mass and muscle mass; and a standard index calculation means 105 for calculating a standard index for insurance enrollment based on at least one of lean body mass and muscle mass.

The application discloses a method for constructing a Parkinson's disease animal model with improved survival rate and application thereof, and relates to the biomedical field, and comprises the following steps: S1, injecting a gepefron solution into the abdominal cavity of an experimental mouse; S2, performing brain stereotactic injection on the experimental mouse by using a 6-OHDA solution; S3, injecting meloxicam into the abdominal cavity of the experimental mouse, and dynamically adjusting the dosage of meloxicam based on the daily weight change of the experimental mouse; S4, performing postoperative nursing on the experimental mouse, including nutritional support and graded gavage; and S5, performing behavior testing, pathological verification and inflammation evaluation on the experimental mouse, and obtaining a Parkinson's disease animal model through the above steps. The application has the advantages of high postoperative survival rate of the animal and high success rate of modeling.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The invention relates to application of STX10 in treatment and prognosis evaluation of kidney cancer. The key effect of the STX10 in the renal clear cell carcinoma is emphasized, and the fact that the expression of the STX10 in ccRCC is remarkably up-regulated is revealed. Overexpression of the STX10 promotes proliferation and migration of ccRCC cells, is an independent risk factor of poor OS, PFI and DSS of the ccRCC and is closely related to poor immunotherapy response, it is clear that the STX10 can serve as a prognosis biomarker and a treatment target of the ccRCC, and development of kidney cancer can be obviously inhibited, the survival rate of patients can be prolonged and prognosis can be improved by inhibiting the STX10 or reducing the biological activity of the STX10. Related molecular mechanisms in the occurrence and development process of the kidney cancer are enriched, sufficient scientific basis and theoretical basis are provided for exploring new kidney cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, accurate treatment can be better achieved, and important social value and scientific significance are achieved.

The application discloses a method for constructing a social novelty defect model through catechol exposure of pregnant mice, and belongs to the technical field of disease animal models. The method comprises the following steps: performing catechol exposure treatment on the pregnant mice, feeding the pregnant mice until childbirth, and waiting for the obtained offspring mice to grow to a required age, so as to obtain the social novelty defect model. The method is capable of precisely matching a key time window of embryonic neural development, and adopts a single catechol exposure mode, so that the method is simple to operate, has a high model formation rate, and has a high survival rate of the mother mice and the offspring. In addition, the induced social novelty defect model of the offspring mice is stable in phenotype and strong in specificity, can simulate the cross-generation influence of maternal pregnancy environment exposure on abnormal social functions of offspring young, and is suitable for mechanism research, drug screening and diagnosis marker development of social impairment diseases such as autism.

The invention discloses an acute pancreatitis early stage grading prediction method comprising the following steps: S1, collecting CT image data of AP patients with different clinical conditions and different equipment sources, and carrying out resampling standardization processing; s2, inputting the CT image into the trained and optimized nnU-Net model, automatically segmenting a pancreas region, and generating a pancreas segmentation mask; s3, extracting multi-dimensional image features by using a radiomics tool, and screening out key prediction features by using a feature screening algorithm; and S4, inputting the screened key prediction features into a pre-trained machine learning model, and outputting a risk prediction result of the patient and a corresponding evaluation index. A pancreas area is automatically segmented by an nnU-Net model, multi-dimensional image features are extracted from a CT image corresponding to a pancreas segmentation mask by using a radiomics tool, objectivity and consistency of feature extraction are ensured, key prediction features are screened out by using a feature screening algorithm, a scientific basis is provided for early recognition and risk assessment of SAP, clinical decision is assisted, and the risk assessment efficiency is improved. The survival rate of the patient is improved.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

The invention relates to an application of NUDT14 in improving the sensitivity of Enzalocamide to prostatic cancer treatment. Through deep research, it is clear that NUDT14 can be used as a key factor for occurrence and development of prostate cancer and generation of enzalocamide treatment drug resistance, activities such as proliferation and metastasis of prostate cancer can be obviously inhibited by inhibiting NUDT14 or reducing the biological activity of NUDT14, the drug resistance of enzalocamide is reversed, the treatment sensitivity of enzalocamide is improved, and the survival rate of patients is prolonged; the prognosis is improved. According to the invention, related mechanisms of drug resistance generation and regulation in the process of treating prostatic cancer by enzalocamide are enriched, sufficient scientific basis and theoretical basis are provided for searching new prostatic cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, accurate treatment can be better realized, and the application of enzalocamide in treatment of prostatic cancer is promoted. The method has important social value and scientific significance.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

This invention belongs to the field of tumor detection and relates to a dynamic evaluation method for the efficacy of Bragg therapy driven by multi-cycle, multimodal peripheral blood data. The method includes the following steps: acquiring peripheral blood multimodal data from patients participating in Bragg therapy, and dividing the peripheral blood multimodal data into a training dataset and a validation dataset; constructing a Bragg therapy efficacy evaluation model using the training dataset, and validating the Bragg therapy efficacy evaluation model using the validation dataset; receiving peripheral blood multimodal data from patients participating in Bragg therapy, and calculating the evaluation results using the Bragg therapy efficacy evaluation model. This invention, by combining long short-term memory networks and graph neural networks, can effectively track the temporal changes of immune cell characteristics, thereby providing a more accurate basis for developing personalized treatment plans for Bragg therapy patients, improving treatment outcomes and survival rates.

The application discloses an antibody or antigen binding fragment against Agkistrodon acutus venom and application thereof. The antibody or antigen binding fragment against Agkistrodon acutus venom comprises three heavy chain complementarity determining regions which can specifically bind to Agkistrodon acutus venom and the amino acid sequences of which are shown in SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8; and three light chain complementarity determining regions which the amino acid sequences of which are shown in SEQ ID NO: 12, SEQ ID NO: 14 and SEQ ID NO: 16. The antibody or antigen binding fragment against Agkistrodon acutus venom can specifically bind to Agkistrodon acutus venom and does not bind to Vipera venom, Vipera russelli venom, Naja naja atra venom and Bungarus candidus venom, and can be used for detection of Agkistrodon acutus venom. The monoclonal antibody of the application has neutralizing and protective effects on Agkistrodon acutus venom, and has important significance for assisting clinical treatment, reducing complications and improving survival rate of patients.

The invention provides a tumor infiltration capacity enhanced TIL and a preparation method and application thereof, and belongs to the technical field of cells. The tumor infiltration capacity enhanced TIL provided by the invention is a TIL which enables the expression of the DGKZ gene to be reduced or the function to be eliminated, and has enhanced tumor infiltration capacity compared with the TIL without the DGKZ gene knockout. The tumor infiltration ability enhanced TIL provided by the invention is higher in survival rate in a depletion induction experiment, and shows depletion antagonism characteristics; experiments for performing stimulation culture on the TIL cells by using PMA show that the cytokine secretion ability is remarkably enhanced compared with that of wild TIL cells. A mouse in-vivo experiment shows that compared with a wild TIL, the DGKZ-edited cervical cancer-derived TIL cell has the advantages that the in-vivo tumor infiltration capacity and retention time are more lasting, the tumor killing capacity is higher, a better treatment effect can be achieved, and the DGKZ-edited cervical cancer-derived TIL cell has an important application value in tumor treatment.

The embodiment of the present application relates to the technical field of breeding management, and discloses a breeding management method for breeding hens, comprising: acquiring a temperature detection image group of each breeding area in a henhouse; acquiring position information of each infrared detection pixel point in the temperature detection image, and performing segmentation processing on the temperature detection image according to the position information to obtain a segmented infrared image; inputting the segmented infrared image into a pre-constructed hen temperature identification model to obtain an identification temperature set of each monitored hen in the temperature detection image; and matching the temperature identification set with a set temperature condition, and if the matching fails, performing early warning according to the position of the hen to remind the corresponding management personnel. The scheme of the embodiment of the present application can monitor the body temperature of the hen in real time, can discover possible health problems such as fever in time, and thus can take preventive measures to avoid the occurrence and spread of diseases. This is helpful to improve the survival rate of the hen and reduce the breeding cost.

The invention provides application of a TTR tetramer in prognosis of a heart failure disease. The invention finds that serum TTR tetramer level reduction and NT-proBNP increase are possibly related to adverse clinical outcome events of heart failure patients, such as total cause death and cardiovascular death; after adjusting potential confounding factors, low TTR levels relate to all-cause death and an increase in all-cause rehospitalization risk. Therefore, the serum TTR tetramer and NT-proBNP can be used as potential biomarkers for prognosis of the heart failure disease and independent predictive factors for occurrence of adverse events. A good prediction index is provided for evaluating and improving prognosis of the heart failure disease, so that the survival rate of a patient is increased, the patient is fully benefited, and the application has huge potential and value in clinical application.

The present invention relates to a composition comprising a TAF10 inhibitor for preventing or treating colorectal cancer. The inhibition of TAF10 was found to lead to suppressing the growth and proliferation of colorectal cancer cells, reducing vascularization, and inhibiting the WNT signaling pathway, and increase the survival rate of patients as analyzed with a large-scale cancer database. In particular, reversal of the cancerization process, which is the differentiation of colorectal cancer cells into normal cells, was confirmed. Unlike conventional anticancer agents that simply induce the death of cancer cells, the present invention can thus be advantageously utilized as a treatment method for converting colorectal cancer cells into normal cells while excluding side effects of normal cell death that may occur during anticancer treatment.

The present disclosure relates to predicting a survival rate of a patient with cancer following a treatment. In some embodiments, one or more processors: apply a large language model to a clinical report to extract a plurality of clinical features; acquire a pre-treatment image and a post-treatment image of the patient with cancer; apply a segmentation algorithm on an annotated volume of interest (VOI) of the pre-treatment image to obtain a first segmented VOI; apply the segmentation algorithm on the annotated VOI of the post-treatment image to obtain a second segmented VOI; determine a plurality of radiomics features and a plurality of deep learning features from the first segmented VOI and the second segmented VOI; and apply a machine learning model to the plurality of clinical features, the plurality of radiomics features, and the plurality of deep learning features to predict the survival rate of the patient with cancer.

This invention discloses a method for assessing shrimp health status based on multi-source information fusion, which relates to the field of data processing technology. The method includes the following steps: acquiring and preprocessing shrimp images at different growth stages; generating training images using artificial labels; extracting features such as shrimp outline length, area, and shell contrast; establishing a target recognition and feature extraction model based on the training images; identifying shrimp in the monitored aquaculture environment and extracting their behavioral characteristic parameters after training; calculating the behavioral assessment influence coefficient and growth assessment influence coefficient; and obtaining water source characteristic parameters to calculate the disease incidence influence coefficient; finally, generating a comprehensive health status assessment index, comparing it with a health judgment threshold, and outputting the health status judgment result. This achieves effective assessment of shrimp health status, real-time monitoring, and early warning, helping farmers take timely measures to prevent disease occurrence and improve shrimp survival rate and economic benefits.

The application discloses a methylation marker combination for detecting early gastric cancer and application thereof. The marker combination comprises 146 methylation sites of 11 DNA regions and a transformation rate control marker region, and the methylation levels of the target regions are significantly different between early gastric cancer patients and healthy people. The kit of the application contains reagents for detecting the methylation degree of the above sites, and supports various high-throughput sequencing methods. The detection system adopts a logistic regression model to calculate a prediction value, multiplies the average methylation rate of each region by a corresponding weight coefficient, adds them together, and compares the sum with a threshold value to make a positive judgment. The application realizes high sensitivity and high specificity for non-invasive early detection, is particularly suitable for non-invasive screening of plasma free DNA samples, can effectively improve the survival rate of gastric cancer patients, can significantly reduce medical expenses, and has a wide clinical application and industrial utilization prospect.

The invention relates to the technical field of biological medicines, in particular to application of a ZNF710 gene in preparation of a preparation for hepatocellular carcinoma diagnosis and / or prognosis evaluation. The invention finds and verifies that ZNF710 is closely related to prognosis of liver cancer for the first time and is a key gene for occurrence and development of tumors, and patients with low expression of the ZNF710 gene have higher survival rate. Therefore, compared with the prior art, a novel liver cancer diagnosis and treatment scheme taking the ZNF710 gene as the molecular marker has relatively high clinical application value and potential.